Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Laser Acupuncture in Rheumatoid Arthritis Geriatric Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04758689
Recruitment Status : Completed
First Posted : February 17, 2021
Last Update Posted : May 6, 2021
Sponsor:
Information provided by (Responsible Party):
A. Sedky, Cairo University

Brief Summary:
Studying the effect of laser acupuncture on geriatric patients with rheumatoid arthritis

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Combination Product: Laser, exercise, and methotrexate Combination Product: Exercise, and methotrexate Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Laser Acupuncture in Rheumatoid Arthritis Geriatric Patients
Actual Study Start Date : November 20, 2020
Actual Primary Completion Date : December 20, 2020
Actual Study Completion Date : December 22, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Laser acupuncture and aerobic exercise Combination Product: Laser, exercise, and methotrexate
Laser therapy at acupuncture points, aerobic exercise, and methotrexate

Experimental: Aerobic exercise Combination Product: Exercise, and methotrexate
Aerobic exercise, and methotrexate




Primary Outcome Measures :
  1. Interleukin 6 (IL-6) [ Time Frame: Baseline ]
    interleukin 6

  2. Interleukin 6 (IL-6) [ Time Frame: 4 weeks ]
    interleukin 6

  3. Malondialdehyde (MDA) [ Time Frame: Baseline ]
    malondialdehyde

  4. Malondialdehyde (MDA) [ Time Frame: 4 weeks ]
    malondialdehyde

  5. Adenosine Triphosphate (ATP) [ Time Frame: Baseline ]
    adenosine triphosphate

  6. Adenosine Triphosphate (ATP) [ Time Frame: 4 weeks ]
    adenosine triphosphate

  7. C-Reactive Protein (CRP) [ Time Frame: Baseline ]
    C-reactive protein

  8. C-Reactive Protein (CRP) [ Time Frame: 4 weeks ]
    C-reactive protein


Secondary Outcome Measures :
  1. Rheumatoid Arthritis Quality of Life (RAQoL) [ Time Frame: Baseline ]
    rheumatoid arthritis quality of life

  2. Rheumatoid Arthritis Quality of Life (RAQoL) [ Time Frame: 4 weeks ]
    rheumatoid arthritis quality of life

  3. Health Assessment Questionnaire (HAQ) [ Time Frame: Baseline ]
    health assessment questionnaire

  4. Health Assessment Questionnaire (HAQ) [ Time Frame: 4 weeks ]
    health assessment questionnaire



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years to 75 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients referred from physician (immunologist) diagnosed with rheumatoid arthritis.

Exclusion Criteria:

  • Patients having the disease overlapping with other connective tissue diseases, such as systematic lupus erythromatosus and systematic sclerosis.
  • History of malignancies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04758689


Locations
Layout table for location information
Egypt
A. Sedky
Cairo, Egypt
Sponsors and Collaborators
Cairo University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: A. Sedky, Principal investigator, Cairo University
ClinicalTrials.gov Identifier: NCT04758689    
Other Study ID Numbers: REC/002-2021
First Posted: February 17, 2021    Key Record Dates
Last Update Posted: May 6, 2021
Last Verified: May 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Methotrexate
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors